Free Newsletter
Merck starts work on vax R&D; center
Merck is preparing to launch construction of a €200 million vaccine R&D facility in the southeastern area of Ireland. The pharma giant says that construction will get started next year and should wrap in 2010.
"The new vaccine and biologics facility will bolster our expanding global vaccines business, which includes products to protect against hepatitis, zoster, rubella, measles and haemophilus," said Merck. "The project will create 170- new high-quality jobs by 2011 across all areas of management, quality control, engineering, research and development and administration."
Irish officials lauded the move as another sign of the country's growing role in biotechnology.
- read the story in Medical Laboratory World
Related Articles:
A bright future for Merck's NC vaccine plant
Merck adds $300M, 180 jobs at NC plant
Merck's McGlynn has key role developing vaccines
Merck warned on vaccine plant problems
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D;: Evolving strategies to rejuvenate R&D; efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges




Click here to get the FierceVaccines email newsletter for FREE!
Be the first to comment